What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

To evaluate the diagnostic and prognostic value of ctDNA in cerebrospinal fluid in gliomas compared to plasma.

December 11, 2025Frontiers in OncologyOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review and meta-analysis reveals cerebrospinal fluid ctDNA outperforms plasma in gliomas, suggesting enhanced diagnostic utility.

To evaluate the diagnostic and prognostic value of ctDNA in cerebrospinal fluid in gliomas compared to plasma.
Systematic review of studies from 2015 to 2025 on ctDNA detection in CSF from glioma patients.
Pooled analyses compared detection rates between CSF and plasma, different collection routes, and assay types.
Assessment of molecular concordance with tumor tissue and clinical correlations.
ctDNA detection in CSF was 82%, while plasma showed only 16%.
Tumor–CSF molecular concordance was 90%.
Higher detection rates in CSF compared to plasma with significant odds ratio of 0.05.

Pérez‐Alfayate et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review and meta-analysis reveals cerebrospinal fluid ctDNA outperforms plasma in gliomas, suggesting enhanced diagnostic utility.